Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Duality BiotherapeuticsFRA:4ZB -1.02%19 Earnings per Share (Diluted) is € as of Jun. 2026. GuruFocus rates FRA:4ZB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,157 Biotechnology companies, Duality Biotherapeutics ranks worse than 98.62% on this metric.
During the past 3 years, the average EPS without NRIGrowth Rate was -103.80% per year.
During the past 4 years, Duality Biotherapeutics's highest 3-Year average EPS without NRI Growth Rate was -103.80% per year. The lowest was -103.80% per year. And the median was -103.80% per year.
Duality Biotherapeutics (FRA:4ZB) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Duality Biotherapeutics Earnings per Share (Diluted) Related Terms
Duality Biotherapeutics Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Duality Biotherapeutics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duality Biotherapeutics Earnings per Share (Diluted) Chart
Duality Biotherapeutics Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Earnings per Share (Diluted)
-0.66
-0.56
-1.62
-4.91
Duality Biotherapeutics Semi-Annual Data
Jun25
Dec25
Jun26
Earnings per Share (Diluted)
-6.28
-0.70
-1.27
FRA:4ZB vs VRTX, REGN, MRNA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Duality Biotherapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duality Biotherapeutics PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Duality Biotherapeutics's PE Ratio falls into.
Duality Biotherapeutics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Duality Biotherapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
What does a Earnings per Share (Diluted) of € mean?
Duality Biotherapeutics (FRA:4ZB) has a Earnings per Share (Diluted) of € as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Duality Biotherapeutics and its competitors. According to the industry distribution chart, Duality Biotherapeutics ranks #1141 out of 1157 companies in the Biotechnology industry, placing it in the top 98.6%.
Is Duality Biotherapeutics' Earnings per Share (Diluted) too high?
Duality Biotherapeutics' current Earnings per Share (Diluted) is €. Based on the distribution chart, Duality Biotherapeutics ranks #1141 out of 1157 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Duality Biotherapeutics ranks #1141 out of 1157 companies for Earnings per Share (Diluted). This places Duality Biotherapeutics in the lower half of its industry. The industry median Earnings per Share (Diluted) is 15.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 15.90, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Duality Biotherapeutics and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duality Biotherapeutics's current Earnings per Share (Diluted) is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current Earnings per Share (Diluted) of €. The current Earnings per Share (Diluted) is €. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current Earnings per Share (Diluted) is € as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score
Get the complete analysis for FRA:4ZB
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4ZB has been successfully added to your 
